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Available online 10 August 2016Orthopaedic implants have been the subject of intense research in recent years, with academics, clinicians and
industrialists seeking to broaden our understanding of their function and potential consequences within the
human body. Current research is focussed on ways to improve the integration of an orthopaedic device within
the body, whether it be to encourage better osseointegration, combat possible infection or stem the foreign
body response. A key emerging strategy is the controlled delivery of therapeutics from the device, which may
take the formof, for example, antibiotics, analgesics, anti-inﬂammatories or growth factors. However, the optimal
device design that gives rise to the desired controlled release has yet to be deﬁned. There are many examples in
the literature of experimental approacheswhich attempt to tackle this issue. However, the necessity of having to
conductmultiple experiments to test different scenarios is amajor drawback of this approach. So enter stage left:
mathematicalmodelling. Using amathematicalmodelling approach can providemuchmore than experiments in
isolation. For instance, a mathematical model can help identify key drug release mechanisms and uncover the
rate limiting processes; allow for the estimation of values of the parameters controlling the system; quantify
the effect of the interaction with the biological environment; and aid with the design of optimisation strategies
for controlled drug release. In this paper we review current experimental approaches and some relevant math-
ematical models and suggest the future direction of such approaches in this ﬁeld.
© 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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1.1. Background
Orthopaedic implants (OIs) have proven to be a very successful ad-
dition to the ﬁeld of medicine. Examples of these devices include plates,
screws and intramedullary rods to stabilise fractures, prosthetic hip and
knee joints, and replacement intervertebral disks. Traditionally, OIs
were designed to serve one of two purposes: either to act as a ﬁxation
device to provide mechanical stabilisation or to replace a joint or
bone, such as a hip replacement. The former is achieved by reducing
the stress and strain on the affected bone, essentially sharing the load.
Themechanical stabilisation of bones via the implant allows for optimal
bone positioning which can be maintained during physiologic loading
and thus the implant aids the natural healing process of bone. OIs
allow for restored mobility, reduced pain and improving the overall
quality of life for millions of recipients the world over [1].
OIs started as simple mechanical devices, however, complications
quickly became apparent. There are many factors to consider, such as
the physical impact the device has on the bone and surrounding soft tis-
sue; the inevitable foreign body response; the possibility of post-surgi-
cal infection; whether or not osseointegration can be achieved (the
successful functional and structural connection between bone and im-
plant) and several other obstacles.
1.2. Challenges
In an attempt to overcome the many challenges facing orthopaedic
device usage, many experimental research approaches have appeared
in the literature, that examine the various aspects of OIs. As well as
the need to ensure that OIs have the necessary mechanical properties
[2–4], the materials from which they are made must be biocompatible
[2,5], and many studies have been dedicated towards investigating the
biocompatibility of novel OI materials [2,3]. These studies include, for
example, determining possible cytotoxic effects and corrosion resis-
tance [2–4]. It has been suggested that many of the remaining chal-
lenges (e.g. osseointegration, inﬂammation, infection and pain) may
be tackled by the local delivery of therapeutics. Infection is one of the
major causes for concern following surgery, and although care is taken
to sterilise the equipment and the implant to be ﬁtted, infections do
arise [5–9].
The local delivery of drugs in orthopaedic applications is not new. In-
deed, antibiotics have for years been routinely delivered locally follow-
ing joint replacements such as prosthetic hips. However, the antibiotics
have been contained within the cement that is used to secure the im-
plant in place [5,8], rather than embedded within the implant itself.
The result is that there is next-to-no level of control over the release:
drug is typically delivered at concentrations well in excess of the mini-
mum inhibitory concentration (MIC) of bacteria [10]. Furthermore, the
high dependence on surface area and porosity of the cement makes it
difﬁcult to control and reproduce a desired release proﬁle, especially
since the drying process of the cement results in the unpredictable for-
mation of cracks and other defects [10]. Recently, there has been amove
away fromOIs which require the use of cement. Themain driver for this
change of tack has been the introduction of OI materials which exhibit
rough surfaces that provide a “snug ﬁt”, rendering the use of cement re-
dundant. There is also a beneﬁt for the patient in terms of a reduction in
the procedure duration, due to the lack of need to wait for cement to
dry.Whilst antibioticsmay in principle be coated onto the rough surface
of these newer implants, to the best of our knowledge, no such implants
have yet made it into clinical practice. The lack of local delivery of anti-
biotics in these applications is a concern, and is certainly an area where
research efforts should be focussed.
Experimental approacheswhich have investigated drug release have
typically contained drug within hollowed out portions of the implant
[10–12], a coating on the surface of the implant [1,5] or a modiﬁedsurface/structure of the implant [13–15]. The drug may be an anti-in-
ﬂammatory, such as dexamethasone, to help with the foreign body re-
sponse; an antibacterial/antimicrobial agent, such as linezolid and
cefazolin, to ﬁght off/prevent infection; analgesics, such as tramadol,
for pain relief; or perhaps even growth factors to encourage wound
healing. Whilst the experiments that have been conducted thus far
show promise for the development of drug-eluting OIs, to the best of
our knowledge none of these prototypes/designs have yet made it into
clinical practice. One of the issues regarding the design of drug-releasing
OIs is that whilst it is clear that controlled release is required, it is not al-
ways clear what the desired release proﬁle is. Controlled release is of
great importance since if the concentration is too high a toxic effect
could occur or if the concentration is too low the desired therapeutic ef-
fect could be lost. The challenge is to be able to maintain a drug concen-
tration level that is within some therapeutic range, often for an
extended period of time. Particularly in the case of antibiotics, care
must be taken to ensure that drug delivery below the minimum thera-
peutic level is avoided, since long-term exposure is associated with an-
tibiotic resistance [2]. In order to be able to control the release for a
givenOI, onemust have a good understanding of thedrug releasemech-
anism(s). Experimental approaches have provided insights in this re-
gard, but when there are a number of possible mechanisms involved,
the relative importance of each is not always clear and so predicting
the effects of changes in system parameters can be challenging. For ex-
ample, from experiments it may appear that diffusion is the dominant
release mechanism for a given drug, but if the drug is replaced with an-
other of substantially lower solubility, then the rate of drug release may
be limited by the rate of dissolution. Varying other system parameters
such as the thickness or porosity of a drug releasing coating; the mate-
rial the coating is made from; or the physico-chemical properties of the
drug itself may result in the dominant releasemechanism changing and
introduce such effects as erosion, swelling, degradation and interactions
between the drug and the material itself.
To the best of our knowledge, no mathematical models of OIs exist
that attempt to solve the controlled release issue, which is unfortunate
as mathematical modelling is capable of helping to determine the key
drug release mechanisms and uncover the rate limiting processes; esti-
mate the values of the parameters controlling the system; quantify the
effect of the interaction with the biological environment; and aid in
the design of optimisation strategies for controlled drug release. It is im-
portant to note that OIs were never engineered to carry and release
drugs, so incorporating drugs into OIs and controlling the release is a
great challenge [16].
1.3. Outline
The purpose of this paper is two-fold. Firstly, it will serve as a brief
overview of experimental approaches which have attempted to aid in
the design of drug-releasing OIs. Secondly, it will outline mathematical
approaches that may allow for a greater understanding of how to con-
trol the release of drug from OIs, such that drug is delivered and main-
tained at the appropriate levels for the correct duration. This paper is
not intended to present a fully comprehensive review of experimental
approaches, but rather to give a feel for the existing experiments, the
challenges that have been faced, the questions that have arisen and to
indicate how mathematical modelling can assist in addressing these
issues.
2. Experimental approaches to enhance current knowledge on drug
release
The ﬁnal clinical outcome is determined by the biological and me-
chanical characteristics of the bone healing process and so the integra-
tion of orthopaedic devices must allow this process to continue and
aid it if possible. To this end, many researchers are looking at various
ways to enhance current OIs or produce new ideas for orthopaedic
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paedic implant designs [10–12], the application of a coating to the im-
plant surface which releases drugs [1,19], altering the surface of the
bare implant to act as a drug reservoir [15,18] and exploring newmate-
rials for device construction which could hold drugs [2,20]. Indeed, nu-
merous experimental approaches have been devised to examine the
combination of drug-elution with an orthopaedic device.2.1. Drug ﬁlled orthopaedic implant designs
Focussing on local infection, Gimeno et al. [11] examined the release
rates of two dry solid antibiotics (linezolid and cefazolin) from hollow
stainless steel (widely used in the manufacture of OIs) medical grade
tubes, where the hollowed-out portion of the tubes acted as a reservoir
for each drug (Fig. 1, Image 1). This was a proof-of-concept study, with
the intention being that the hollow tubes would be developed into
drug-eluting ﬁxation screws. Each tube was ﬁlled with either linezolid
or cefazolin andmachined to have either 2, 4, 6 or 8 equidistant oriﬁces,
throughwhich the drug could be released into the surrounding simulat-
ed body ﬂuid (SBF, Kokubo solution). The in vitro experiments were
performed in triplicate, in stirred conditions, without the renewal of
SBF. The authors demonstrated that the drug release rate could bemod-
iﬁed by varying the number of oriﬁces in each tube. However, theywere
not able to fully explain the similar release proﬁles of both drugs in the
case where the tubes had 2 oriﬁces, despite cefazolin having a much
greaterwater solubility,whereas the release proﬁlesweremarkedly dif-
ferent for 4, 6 and 8 oriﬁces (Fig. 2).
In addition, the release proﬁles for linezolid were highly non-intui-
tive, especially for the tubes with 6 and 8 oriﬁces. The authors also test-
ed the infection ﬁghting abilities of the drug-ﬁlled tubes and used the
tubeswith 4 and 6 oriﬁces, alongwith a control which had no antibiotic.
They found that both drugs were able to diffuse out of the tubes with 4
and 6 oriﬁces into the surrounding medium and kill off the bacteria. An
increasing bacterial population was found in the control experiment.Fig. 1. A selection of experimental approaches: Image 1 (top left): prototype drug releasing tub
porouswalls by Perez et al. [12]. Image 3 (bottom left): a view of the nanoﬁbres experimentedw
experiments by Aninwene et al. [18].An experimentwhich features a two-stage antibiotic-eluting device,
was conducted by Perez et al. [12], who examined the release of linezo-
lid from hollow stainless steel medical grade tubes with porous walls
(Fig. 1, Image 2). The hollowed-out sections of each tube were ﬁlled
with spherical mesoporous silica microparticles loaded with linezolid.
Three tubes were experimented with under stirred conditions and the
resultant release proﬁles show an increasing concentration of the anti-
biotic in the surrounding SBF (which was replenished once). According
to the authors, noticeable differences in the release proﬁles may be due
to slight variations in the porosity of each tube during the manufactur-
ing stage; small differences in the amount of drug that was loaded into
the particles; or perhaps packing density [12]. Perez et al. demonstrated
the bactericidal effect of these tubes, observing a 3 orders of magnitude
bacterial growth reduction after 48 h. It was noted that the release pro-
ﬁle of linezolid ﬂattened out at a concentration that was much lower
than the predicted maximum concentration, suggesting that the con-
centration of drug in both the SBF and the device may have reached
an equilibrium. In a real-life setting, the ﬂuid surrounding an implant
would be continuously renewed and so further drug release is achiev-
able: this was tested by renewing the media and further drug release
was conﬁrmed (Fig. 3).
It is also noted that this design offers good ﬂexibility since it is a two-
stage release device and depending on the release proﬁle required, this
could be achieved via altering the characteristics of the silica particles
and the porous wall of the tube independently.
The aforementioned implant design was further tested within an
ovine study by Gimeno et al. [10], although the device was instead
ﬁlled with solid linezolid rather than drug-loaded particles. Their in
vivo experiment was successful, as after 7 and 9 days following the
addition of bioﬁlm forming bacteria, the sheep did not show any
signs of infection. This altered implant was also tested in vitro by
submersing the device in SBF. The results showed that the implant
released almost 75% of the antibiotic during the ﬁrst four days and
sustained release for at least one week. The release proﬁle obtained
from the experiment was almost linear (Fig. 4), in contrast to thee by Gimeno et al. [11]. Image 2 (top right): a similar prototype drug releasing tube with
ith by Song et al. [17]. Image 4 (bottom right): an example of a nanotubular surface in the
Fig. 2. Release proﬁles for drug-ﬁlled tubes with varied numbers of oriﬁces (pinholes). Reproduced from [11].
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particles (Fig. 3).2.2. Drug releasing coatings for orthopaedic implants
Drug releasing coatings have been given much consideration in re-
cent years in orthopaedic applications [1,2,6,19,21]. These coatings can
take several forms. For example, bone-like materials such as Hydroxy-
apatite have been shown to be capable of storing and releasing drugs
[1,2,19], whilst exhibiting favourable biocompatibility properties. Hy-
droxyapatite may aid osseointegration, however, the lack of controlla-
bility of drug release has been cited as a potential issue [17]. OtherFig. 3. Release proﬁle from two-stage antibiotic releasing implant, indicating that drug
release continued after renewing release media. QF/Q0(%) represents the cumulative % of
drug released. Reproduced from [12].coatings considered include durable/biodegradable polymers [9,22],
gels [23] and nanoﬁbers [17,24].
In an attempt to tackle the issue of post-surgical infection associated
with the implantation of an orthopaedic device, Kaur et al. [22] assessed
the drug-eluting and antibacterial qualities of polymer/drug coated
Kirschner wires (K-wire) in vitro. K-wires were coated with a biode-
gradable poly-D,L-lactide (PDLLA) and linezolid mixture. PDLLA is a
polymer that is used for coating other medical implants and is noted
for its biocompatibility and mechanical stability [22]. Three polymer/li-
nezolid mixtures were used (2.5%, 5% and 10% linezolid), and K-wires
were dipped three times to ensure an even coat. Two drug-free wires
were also used, with the ﬁrst featuring a polymer-only coating, and
the second had no coating at all. The K-wires were suspended in
bacterial solutions containing either MRSA (Methicillin-ResistantFig. 4. Cumulative drug release from a porous hollow implant, showing an almost linear
proﬁle. Reproduced from [10].
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aureus), so that bacterial cells could adhere to the surface of the K-
wires. The K-wireswere placed into phosphate buffered saline (PBS) so-
lution and during a 120 h period, samples were taken to determine the
amount of linezolid released. The results of the experiment showed a li-
nezolid concentration above the MIC for all three polymer/linezolid K-
wires (Fig. 5).
The wires with the two highest concentrations were reported to ex-
hibit sustained release of linezolid and although the linezolid concentra-
tions sampled at 120 h was minimal, it was between 8 and 16 times
higher than the MIC. In the case of the wire with the lowest concentra-
tion, there was a peak concentration at 24 h, after which, the linezolid
concentration began to decrease. The results also showed a signiﬁcant
decrease in the number of bacterial cells adhered to the surface of the
wires. The authors mention that the effectiveness of devices such as
these is dependent on the release proﬁle of the drug, as a high initial re-
lease rate and a subsequent prolonged period of drug release is required
to ensure that the drug concentration is above the MIC. Although the
bacteria used in the experiment were not completely eradicated, Kaur
et al. note that the signiﬁcant reduction in their numbers would go a
long way to limit the possibility of infection post-surgery, since the im-
mune system could handle the remaining bacteria.
Argarate et al. [9] investigated the drug-eluting qualities of poly(D,L-
lactide-co-lactide) (PLDL) disks coated with the biodegradable polymer
poly(L-lactic acid) (PLLA). The drugs used in the experiment were euge-
nol (EG) and dexamethasone (DM), which gave the PLDL disks both an-
tibacterial and anti-inﬂammatory qualities. The PLDL disks were coated
by dipping them into solutions of varying concentrations of PLLA. The
authors observed that the thickness of the polymer coating could be
modiﬁed via altering the concentration of PLLA in solution, with coating
thickness increasing with concentration. For the in vitro drug-elution
experiments, they prepared three sets of coating for the PLDL disks: 1)
a direct coating of EG; 2) a layer of PLLA mixed with EG and; 3) a
layer of PLLA and EG followed by a second coat of PLLA and DM. Three
disks in each coating set were used in the experiments. The disks
were immersed in PBS solution, in a water bath shaker. At regular
time intervals, up to 8 weeks, samples of the PBS solution were taken
to evaluate drug release and fresh PBSwas added to replace the samples
taken.
It was observed that the polymer coating was uniformly distributed
on the PLDL disks and that a rough surface was obtained from the coat-
ing, whichmayhelp in osteoblast adhesion [9]. Itwas noted that a direct
coating of EG delivered drug rapidly when compared to the single and
bi-layered PLLA coats. It was shown that the bi-layered disks had aFig. 5. Concentration proﬁles of drug released fromK-wires. Three drug/polymermixtures
used: 2.5%, 5% and 10% indicated by K1, K2 and K3 respectively. Reproduced from [22].total drug delivery less than that obtained from disks with one layer of
coating and it was suggested that this may be due to the relatively
large diffusion distance, with a bi-layer coating, to the surroundingme-
dium. The combined bi-layer disks of both DM and EG showed that DM
was delivered quicker than EG, this was due to DM being contained
within the upper layer, which resulted in a quick release during the
ﬁrst week, after which the release plateaued up to 8 weeks. The inner
layer, containing EG, delivered almost half of the drug within 4 days,
then steady release for the remaining ﬁrst week was observed.
After which, the release plateaued up to the 8th week of the
experiment. (Fig. 6). The authors concluded that controlled
sequential release of two drugs from a bi-layered coating on implants
is possible.
Radin et al. [23] examined the release of vancomycin from thin sol-
gel ﬁlms on titanium alloy plates, a material often used in fracture ﬁxa-
tion. Their research was inspired by the fact that sol-gel ﬁlms are bio-
compatible and that room temperature processed silica sol-gels are
nanostructured andporousmaterials [23],which are ideal for controlled
release. The experimental setup consisted of Ti-6Al-4V (an alloy of tita-
nium) strips which were dipped into a sol-gel solution containing dif-
fering vancomycin concentrations numerous times to apply a varying
number of layers to the alloy samples. Studies of the degradation of
the sol-gel ﬁlms and of the release of vancomycin in PBS solution
were carried out, with daily renewal of themedia. Their results showed
a time-dependent release of vancomycin and when the coatings were
comprised of 2 or 3 layers, a signiﬁcant increase in the release rate,
the total amount of drug released and duration of release was found
(Fig. 7).
A close connection between the degradation rates and the release
rates was inferred. The authors concluded that a long-term release can
be achieved by the use of multi-layered coatings and that the degrada-
tion and release rates can be tailored by varying the parameters in the
process of producing the sol-gel. The ﬁndings also allude to the conclu-
sion that coating degradation is a governingmechanism in the release of
the drug. This experiment highlights the suitability of a sol-gel coating
as a drug releasing method and this approach has the beneﬁt being
able to vary multiple parameters to tailor the release rates depending
on the application. The possibility of applying layers which contain dif-
ferent therapeutics is mentioned, for example a combination of antibi-
otics and growth factors [23].Fig. 6. Cumulative release of the drugs from PLDL disks coated with PLLA. The drugs
Dexamethasone (DM) (▲) and Eugenol (EG) (■) were considered. Reproduced from [9].
Fig. 7. Cumulative release of vancomycin from sol-gel ﬁlms with different layers (L).
Reproduced from [23].
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hol (PVA) core-sheath nanoﬁbre (NF), blended with hydroxyapatite
nanorods (HA) and type 1 collagen (Col) via an electrospinning tech-
nique [17] (Fig. 1, Image 3). The PCL/Col mixture acted as a suitable
outer barrier, referred to as a “sheath” in the experiments, since it de-
grades slowly [17]. The mixing of HA to the PVA increased surface
roughness and the mechanical strength of the NFs. This mixture was
the core of the NFs and was designed to mimic bone tissue and act as
a drug reservoir.
Controlled release experiments of Doxycycline (Doxy) and Dexa-
methasone (Dex) (an antibiotic and an anti-inﬂammatory respectively)
were carried out to evaluate the NFs as a coating. To assay the release of
Dex and Doxy from the NFs, samples of NF were soaked with distilled
water and the concentrations of Dex and Doxy were measured via a
spectrometer. In both experiments, release media was not renewed or
stirred. PCL and PVA ﬁbres were used separately initially to assess
their bactericidal ability and then combined to form a core-sheath NF
structure. The results of the experiments showed that PVA ﬁbres blend-
edwith Doxy had a burst release of drugwithin theﬁrst 10 h,with com-
plete release within 48 h. However, when a PCL sheath was included in
theNFs, the duration of release of Doxywas increased to over 700 h, due
to slow degradation of the PCL sheath [17]. When Doxy was applied to
both the core and the sheath of the NFs, the bactericidal effect was
found to be long lasting, the release of Doxy from the core-sheath NFs
were able to provide sustained Doxy release for at least 152 h [17].
Dex showed similar release behaviour to Doxy when blended with
PVA, i.e. a burst release within 10 h and complete release within 48 h.
With a PCL sheath added, Dex release was found to have increased to
over 150 h, with a slightly further increase to release duration when
Dex was also added to the PCL sheath.
The authors concluded that their experiments showed that the NFs
produced were capable of controlling the release of Doxy and this was
successful in inhibiting MRSA colonisation and preventing possible in-
fection in vitro. It was also shown that the NFs displayed good biocom-
patibility and osteoconductivity, through the measure of cellular
adhesion to the NFs.
2.3. Surface and structure alterations of orthopaedic implant materials for
drug release
An area of research that has gathered much attention is materials
from which orthopaedic devices will be manufactured. This is a rather
complex area of study as many characteristics of a proposed material
and the resulting impact on the body have to be considered. The mate-
rial must display a suitable set of mechanical properties, such as com-
pressive/tensile/fatigue strength and density and of course the
material must not induce a toxic effect. The precise application for the
material will also play a role in its suitability, for example, the materialmay require greater wear or corrosion resistance than others as it may
have to be situated in adverse conditions in the body [2]. Altering the
surface of an implant to produce nanotubes, for example, has many ad-
vantages. As well as acting as drug reservoirs on the implant surface [2,
13,15,19], the strong mechanical properties of some nanotube struc-
tures can be used to reinforce implants [13,19]. Additionally, it has
been hypothesised that nanotubes made of metal oxides or alloys may
improve osseointegration [13,15,19] and cell viability [15,19,21], by
the fact that the rougher surface is more akin to bone than implants
with a smooth surface [13,15,18,19].
Aninwene et al. [18] examined the effect of a drug-coated anodised
nanotubular surface on osteoblasts (Fig. 1, Image 4). Anodised nano-
tubes increased the roughness of the surface of the titanium in their ex-
periments which resulted in the titanium having a surface which is
similar to natural bone. Osteoblasts tend to adhere to surfaces which
are likened to bone, in terms of chemistry and roughness, and it is pre-
cisely thiswhich inspired their research [18]. They also noted the poten-
tial for these nanotubes to act as reservoirs for antibiotic, anti-
inﬂammatory and bone-growth promoting drugs [18]. The authors
also note that there are possible surface tension issues that could im-
pede drug loading and noted that when soaked with SBF, the calcium
phosphate crystal formations on the titanium surfacemay provide opti-
mal surface energy to efﬁciently coat the anodised nanotubular titanium
samples with drugs.
In their experiments they prepared anodised and non-anodised
samples of titaniumand coated themwithdrugs, either penicillin/strep-
tomycin or dexamethasone via simple physical adsorption or by soaking
the samples in SBF, which contained the drugs. They also seeded osteo-
blasts onto the sampleswhichwere then cultured. Their results showed
that osteoblasts adhered in greater numbers to the anodised titanium
than the non-anodised (Fig. 8) and that the samples whichwere soaked
with SBF containing the drugs eluted more penicillin/streptomycin and
dexamethasone than samples whichwere coated by simple adsorption.
This experiment has very encouraging results: the combination of bet-
ter osteoblast adhesion and drug-elution from a nanotube structured ti-
tanium surface is a potential way to combat the issues related to the use
of OIs.
Lyndon et al. [2] have reviewed several of the latest metallic and
drug/device combinations and outlined some promising materials for
use in orthopaedic applications, in particular a porous magnesium
foam was mentioned. Aghion et al. [20] examined the viability of drug
carrying and release from a magnesium foam. They used a magnesium
alloy which was reduced to a powder for the milling process to obtain
the magnesium foam. The level of porosity of the foam was controlled
by using different quantities of ammonium hydrogen carbonate (spac-
er), with varying diameters, and mixing this with the magnesium
alloy powder. Once the resultant powder was in the ﬁnal stage of pro-
cessing, the ammonium hydrogen carbonate evaporated due to the
high temperature. Mixtures containing 10% and 25% spacer material
was used. The authors noted that the average pore size in the magne-
sium foam when 25% spacer material was used, was around 140 μm
and with 10% spacer material it was 40 μm. It was also found that
using a mixture with 25% spacer material, produced a foam with sig-
niﬁcantly more interconnected pores, whereas the 10% spacer mix-
ture only had interconnected pores close to the surface, thus
limiting its ability to carry and release a signiﬁcant amount of drug
[20]. The magnesium foams were loaded with the antibiotic genta-
micin by immersing the foams in a concentrated gentamicin solu-
tion, then evaporating the water to leave behind solid gentamicin
within the foams.
The foams were placed into PBS solution and the concentration of
gentamicin was measured. It was found that the release of the drug
from magnesium foam made with 10% spacer was relatively quick and
could be explained by the lack of interconnected pores throughout the
foam, with such pores only being present close to the surface of the
foam. The magnesium foam made with 25% spacer had considerably
Fig. 9. Concentration proﬁles of gentamicin release frommagnesium foams with 10% and
25% spacer material. Reproduced from [20].
Fig. 8.Osteoblast density after culturing for 1 and 2 days, following drug release from anodised nanotubes. Abbreviations: U, unanodised Ti; A, anodised Ti; A+ PS, anodised+ penicillin/
streptomycin physical adsorption; A + DEX, anodised + dexamethasone physical adsorption; ASH, anodised, heat-treated and SBF-soaked Ti; ASH + PS, as previous but with penicillin/
streptomycin; ASH + DEXA, as previous but with dexamethasone. Notes: Data = Mean ± SEM; n= 3; *p b 0.1 compared to unanodised Ti; **p b 0.1 compared to the respective drug
coated via physical adsorption. Reproduced from [18].
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absorb more drug (Fig. 9).
The degradation of the magnesium foam was found to rise by in-
creasing spacer content, which was expected since using more spacer
increases the surface area of the foam and so a greater area is exposed
to the PBS solution [20]. The experiment demonstrates that the overall
porosity of the material can be altered depending on the amount of
spacer used. However, Aghion et al. note that the reduced time for com-
plete degradation of the magnesium foam limits its use to applications
where drug release is required for a limited time [20].
3. Mathematical methods
To the best of our knowledge, no mathematical models exist in the
literature which focus speciﬁcally on therapeutic delivery from OIs.
This is somewhat surprising since, there are countless examples of
where mathematical modelling has been used effectively in other
drug release applications. Some of these studies focus on a speciﬁcdrug-releasing implant (e.g. coronary stents), whereas others focus on
drug release from particular materials or structures, many of which
are candidates for OIs. Therefore, it is entirely possible that several
existing published models will ﬁnd application in designing enhanced
OIs, whilst others, with some modiﬁcations may also prove useful.
With the growing acceptance that the release of drugs fromOIs is the fu-
ture, it seems sensible to learn from the development of more advanced
drug-releasing implants. Using the example of coronary stents, in the
early days a purely empirical approach was adopted to device design,
with the focus on a combination of in vitro and in vivo animal experi-
ments. However, it quickly became apparent that the use of mathemat-
ical and computational modelling could not only reduce the number of
experiments, but also save on the costs and time associated with addi-
tional experiments [25,26].
It is useful, however, to remember that amathematicalmodel, much
like an experiment, is an approximation tool: if a model of the release of
a drug from an implant ﬁts experimental data well, it may not capture
the whole picture, as simpliﬁcations are usually required. A mathemat-
ical model that has great predictive qualities can be a signiﬁcant contri-
bution to the understanding of the bigger picture and conﬁdence in a
model is enhanced by altering the experimental conditions and then
comparing to the predicted results. Once validated, the parameters
within the model can also be varied and the resultant release proﬁles
compared, without the need to rerun experiments [25,27].3.1. Drug release mechanisms
To model drug release mathematically, one must have a level of un-
derstanding of the mechanisms of drug release within the particular
system. This can be tricky to pin down, however, by comparing the re-
sults of an initialmodelwith experimental data, it is often possible to as-
certain whether additional mechanisms need to be included, or indeed
removed from themodel. Drug release from amedical devicemay be fa-
cilitated by a number of mechanisms, such as diffusion, swelling, disso-
lution, convection, erosion and degradation, amongst others, although
in reality it is likely a combination of mechanisms that govern drug re-
lease [25,26,28].
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term “release mechanism”: in some cases, it is regarded as the way
drugmolecules are transported or released and in others; it is a descrip-
tion of the processeswhich inﬂuence the release rate. For example, they
note that the release mechanisms in poly(lactic-co-glycolic acid)-based
(PLGA) devices are diffusion, osmotic pumping and erosion. The release
rate is usually said to be diffusion-driven ﬁrstly and then controlled by
degradation/erosion in the later stages [29]. However, it is stated that
more knowledge is required to form the bigger picture of these mecha-
nisms and that comes from the understanding of the underlying pro-
cesses which drive them, such as water absorption, hydrolysis and
erosion [29]. The authors state that for PLGA-based systems, there are
only four ways for drug to be released: 1) transport through the poly-
mer; 2) transport through water-ﬁlled pores; 3) erosion of the polymer
encapsulating the drug; and 4) osmotic pumping [29]. From these
routes of drug release, a much larger system of processes which inﬂu-
ence them can be found. However, it is often the case that the level of
detail required in the mathematics, to adequately capture the release
proﬁle, is relatively small.
3.2. Some existing mathematical models describing release mechanisms
There are, of course, countless mathematical models describing re-
lease mechanisms, covering a whole range of applications. Here we
mention two particularly relevant publications. McGinty and Pontrelli
[30] recently provided a general model of coupled drug release and tis-
sue absorption which may be applicable to certain OIs (Fig. 10). Their
ﬂexiblemodel allows for the consideration of bothdissolution anddiffu-
sion within a durable polymer coating, with the former depending on
both the dissolution rate and the solubility of the drug. The model
doesmake a number of assumptions, including an idealised one-dimen-
sional geometry and the polymer is assumed to be instantly fullywetted
following insertion. However, in contrast to much of the drug delivery
literature, their model importantly accounts for drug transport within
tissue following release. Such amodel, which incorporates the biological
environment, is likely to be crucial if in vivo release is to be modelled.
Their model of drug transport within tissue is very general and can be
used in cases where diffusion and/or convection and/or binding are at
play. A number of binding mechanisms can be accounted for, including
nonlinear saturable irreversible binding; linear reversible binding and;
linear irreversible binding. Therefore, this model can potentially predict
the binding of drugs released from OIs or other implants to biological
tissue. Special cases of themodel are given and it is noted that particular
circumstances could arise in which a process is insigniﬁcant in contrast
to the others. For example, if the drug has a very high solubility and/or a
very low initial concentration, the drug will promptly dissolve and so a
diffusion model is sufﬁcient [30]. McGinty and Pontrelli provide a case
study in which the model is applied to a drug-eluting stent (DES)
(a stent is a mesh-like supporting scaffold that is inserted into arteries
where blood ﬂow has become unsafely restricted [27]). WhenFig. 10. A general model of coupled drug release and tissue absorption [30]. Bound drug and fr
drug-containing coating of thickness l0 and biological tissue of thickness l1, respectively. Th
coefﬁcient whilst 0 b α b 1 depends on the dissolution model studied. D1 and v1 are the diff
binding on and off rates and the density of binding sites, respectively. Full details, along with bcompared with in vivo experimental data, the model showed good
agreement [30].
Lauzon et al. [31] reviewed growth factor delivery systems and listed
numerous existing mathematical models that could potentially be used
tomodel growth factor release. In contrast to themodel of McGinty and
Pontrelli, all of these models account for drug release only, and do not
model drug transport post-release. The mechanistic and semi-empiri-
cal/empirical models presented are based on the drug transport mech-
anisms of diffusion, swelling and erosion. Another mechanism, in
which both mechanistic and semi-empirical models are listed, centres
on the possible interactions between the drug and the device: these
are known as “Afﬁnity-based models” [31]. The limitations of the
models provided generally revolve around the assumptions, such as
perfect sink boundary conditions and constant diffusivity. Other draw-
backs are mentioned, which highlight that somemodels do not capture
the inﬂuence of certain processes, such as depletion of the drug through
biological interactions.
It isworthmentioning that the presentation of themodels by Lauzon
et al.may encourage a “pick andmix” approach tomathematicalmodel-
ling, where one would simply select a model based on the circum-
stances of a particular system. Whilst in many cases this could be
appropriate, we urge some caution: the tabulatedmodels do not always
provide sufﬁcient details regarding the assumptions that were made in
deriving the equations. For example, themodels are all one-dimension-
al, yet no detail is provided as to the validity for an arbitrary device ge-
ometry and it is not always clear what experimental conditions are
considered, e.g. stirred, unstirred, inﬁnite sink, etc. It is recognised by
the authors that the models may not, in fact, be suitable for growth fac-
tors. One important difference is that growth factor proteins can be
much larger than drug molecules [32] and so particle size consider-
ations may need to be taken into account. Mathematical modelling is
ﬂexible, but careful consideration of the releasemechanisms, the geom-
etry of the proposed device and the experimental conditions, must be
accounted for. Although general models do exist in the literature
(e.g. Lauzon et al. and McGinty and Pontrelli), they are general only
for a particular set of circumstances and conditions. Even when a
mathematical model exhibits great predictive qualities for a particu-
lar system, a change to the device, such as a change of material or ge-
ometry, or a change to the experimental setup such as choosing to
stir the release medium, may not allow for such a model to maintain
its usefulness, and in these circumstances a new model may need to
be devised.
In spite of the intricacy of the processes that can occur in a drug de-
livery system, mathematical modelling can be a light at the end of the
tunnel. Carefully considering the underlying processes mathematically
can lead to the conﬁrmation or discovery of the main processes that
drive the mechanisms of drug release. Some processes may have a
much greater inﬂuence on the release rate than others and so it is im-
portant to identify them if we seek to attain controlled release for a par-
ticular application.ee drug are represented by b and c, respectively, whilst the subscripts 0 and 1 refer to the
e parameters β0, S, D0 represent the dissolution rate, drug solubility and drug diffusion
usion coefﬁcient and magnitude of convection in tissue, whilst k1, k−1 and bmax are the
oundary, interface and initial conditions can be found in [30].
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Tzur-Balter et al. [33] experimentedwith drug release frommesopo-
rous silicon and then sought to mathematically model the release of the
drug. In their experiment, they measured the release of the anti-cancer
drugMitoxantrone (MTX) from two samples ofmesoporous silicon, one
in an unaltered form (PSi) and the other chemically altered using 1-
dodecene (d-PSi). The chemical altering process is hydrosilylation, in
which the surface of the silicon is bonded with hydrogen, resulting in
a more stable silicon platform [34]. The samples were loaded with
MTX and placed into PBS solution. Measurements of the released drug
were taken by sampling the media and then replacing it with fresh
PBS solution. Their results showed that the chemically altered silicon
sample (d-PSi) sustained release for much longer and that the sample
had eroded far less than the PSi sample. It was hypothesised that,
based on the results of the experiment, the release of MTX from the
PSi samplewas by the combination of twomechanisms, those being dif-
fusion of MTX and the erosion of the sample [33]. The other sample, d-
PSi, had not eroded nearly as much and so the release rate of MTX was
slower. The authors concluded that since the release of MTX was much
quicker than the erosion in the case of the d-PSi sample, the governing
mechanism of release of MTX from this sample was diffusion [33].
Tomathematically model this experiment, a relatively simplemodel
which combined the erosion of the samples and diffusion of the drug
was devised. Fick's second lawwith a uniform, constant drug concentra-
tion as the initial condition, and inﬁnite sink and zero-ﬂux boundary
conditions were proposed (Fig. 11). The fraction of mass of drug re-
leased in the experiment is given by Crank's classical solution [35],
which Tzur-Balter et al. modiﬁed to include the effects of the erosion
of the porous wall of the silicon. It was assumed that the diffusivity
was the only parameter in the bulk porous domain that experiences sig-
niﬁcant changes due to erosion and so the fractional drug release equa-
tion was altered to include this effect. Diffusivity was modelled by
deﬁning a function σ(t) which took erosion into account.
The model was found to ﬁt the data obtained very well. To increase
the validity of the model, the release proﬁles obtained from the unal-
tered Crank model and a model which did not account for erosion and
the other processes which affected diffusion, were added to the plots.
These twomodels did not ﬁt the data well, both of which overestimated
the release of MTX in the early stages of release and both
underestimatedMTX release, after approximately 2 h with the PSi sam-
ple data. For the d-PSi sample data, both of the models in this case
overestimated MTX release between 15 and 70 h [33]. To show that
their model is adaptable, the authors plotted the model alongside
existing experimental data [36] of dexamethasone release from dodecyl
modiﬁed porous silicon samples. Their model was able to ﬁt this data
well, but it was noted that had there been data on the mass change in
the silicon samples due to degradation, the model would have had a
more accurate ﬁt as the erosion of the samples would have been better
approximated [33].Fig. 11. Illustration of a mathematical modelling approach for drug release from porous silicon.
of drug released is given by q. The parameter σ represents a time-dependent diffusivity as a res
pores at time t and the initial mass respectively [33].Kumeria et al. [14] monitored drug release from nanoporous anodic
alumina (NAA) under dynamic ﬂow conditions (Fig. 12). In the experi-
ment, high-purity aluminium foils were obtained and prepared so that a
self-ordered nanoporous layer was achieved, with a pore diameter
range of 30–35 nm and a pore length of, approximately, 4.5 μm [14]. In-
domethacin (an anti-inﬂammatory drug) was loaded in three different
ways into theNAA samples: 1) drugwas load into the pores and the sur-
face of the NAA sample; 2) drug was loaded solely into the pores of the
NAA sample; 3) drug was loaded only on the surface of the NAA sample
[14]. Kumeria et al. used reﬂectometric interference spectroscopy to
monitor the release of the drug from the NAA samples, whilst also ex-
posing the samples to varied ﬂuid ﬂow rates, those being 0, 10, 30 and
50 μL/min. The ﬂuid used was PBS solution [14]. The inspiration for
this approach to assess drug release is due to drug release evaluation
being commonly carried out in a batch observing process under static
conditions, which is limited in that it does not capture the in vivo effects
on drug release [14]. In static experimentation, the releasemedia is con-
tinuously receiving drug and will eventually become saturated and so
the concentration gradient between the drug-eluting sample and the
media will be reduced. This reduction will have an effect on the overall
rate of drug release, potentially giving inaccurate results and so moni-
toring drug release under dynamic ﬂow conditions should help reduce
the inaccuracy of the data whilst improving the simulation of in vivo
drug release.
The results obtained from the experimentswere compared to data of
drug release from NAA samples under static conditions and theoretical
values obtained from a modiﬁed Higuchi equation in an attempt to
identify the governing mechanism of drug release [14]. Under the static
conditions the results show a burst release of the drug from the NAA
sample, during which 75% of the drug was released in the ﬁrst
100 min of the experiment. The release was then steady for the next
4 days, during which 100% of the drug had been released [14]. The
Higuchi equation is founded upon Fick's second law andmodels the re-
lease of drug from insolublematrices [14]. Assuming perfect sink condi-
tions and that the initial drug concentration is signiﬁcantly higher
within the drug-releasing device than the surrounding media, the
Higuchi equation can describe diffusion controlled release of both
water soluble and poorly water soluble drug from non-degradable po-
rous devices [14].
The rate of drug release was conﬁrmed to be inversely proportional
to the square root of time [14],which is obtained from theHiguchi equa-
tion automatically. Fitting the model to the release data, Kumeria et al.
were able to ascertain the release rates under dynamic ﬂow. It was
noted that at a ﬂow rate of 50 μL/min, the drug release rate was approx-
imately 4 times that of drug release in static conditions. However, at the
lower ﬂow rates, 10 and 30 μL/min, the drug release rates were compa-
rable to the release rate in static conditions. The authors concluded that
a faster ﬂow rate increased the amount of drug release from the NAA
implants and with the results of the experiment and the simple mathe-
matical model, it was established that ﬂuid ﬂow can have a signiﬁcant
inﬂuence on the release rate [14]. The high values of the coefﬁcients ofBoundary and initial conditions are shown. Reproduced from [33]. The cumulative fraction
ult of opening pores. L is the ﬁlm thickness, whilem(t) andm0 are the mass of drug in the
Fig. 12. Illustration of drug release phases from nanoporous alumina under dynamic ﬂow. Reprintedwith permission from [14]. Copyright (2013) American Chemical Society. The simple
model used is a modiﬁed Higuchi equation wherem(t) is the mass of drug released at time t,M is the initial mass of drug and a and b are ﬁtting parameters. The rate of drug released is
expressed in terms of a parameter k, which was found to vary for different ﬂow rates [14].
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pendent on the square root of time, which is a key trait of Fickian diffu-
sion [14].
3.4. Mathematical modelling of drug release from porous structures
McGinty et al. [37] adopted a mathematical approach to predict pla-
nar drug release frombulk nanoporousmaterials, and showed that drug
release from nanotubular and smooth surface systems emerged as spe-
cial cases.Whilst their focus was on polymer-free DES, it was noted that
the models could in principle be applied to drug release from
nanoporous drug-releasing implants in general. Their model assumes
that the drug dissolves on a moving front, before diffusing through
water-ﬁlled pores and into the release medium (Fig. 13). Additionally,
the possibility that drug may adhere to the walls of the pores is
accounted for through a linear reversible reaction.
Despite these intricacies, a well-posed initial boundary value prob-
lem was formulated and the resulting moving boundary problem was
solved analytically. One of the advantages of their approach is that
theywere able to derive an analytical solution, allowing for direct calcu-
lation of the release proﬁle of the drug [37]. A model for the two-stage
release from a layer of drug on a DES surface and then the subsequent
release from a nanoporous layer containing drug [37] is also provided.
The key parameters of the system which have a dominating inﬂuence
on drug release are identiﬁed and design considerations are provided
so that a release proﬁlemay be tailored to suit the particular application.
By making the assumption that the absorption and desorption rates
are much quicker than the rate of diffusion (the “equilibrium assump-
tion”), the authors derived a one-dimensional form of Fick's second
law, where the diffusion coefﬁcient is referred to as the apparent diffu-
sion coefﬁcient and this single parameter takes into account the effects
of porosity, absorption, desorption, tortuosity and constrictivity [37].
Both stirred and unstirred cases were considered for the model. One
of the key ﬁndings was that dissolution is an order of magnitude fasterFig. 13. Illustration showing an idealisedmathematicalmodel of drug release from a bulk nanop
represent the concentrations of drug in water, pores and bound to pore walls, respectively.
dissociation constant, cs is the drug solubility and ϕ and ϕb are porosities. The parameter s is t
The dissolution of the pure drug layer is given in terms of error functions, whilst the drug rele
ﬂux at x=−Lp [37].in stirred conditions compared with unstirred: this conclusion directly
arose from mathematical analysis of the underlying equations.
3.5. Mathematical modelling of drug release from stents and lessons to be
learned
One of the key areas where mathematical modelling has greatly en-
hanced understanding of drug release and the mechanisms that control
it, is in simulating drug release from stents. Using a mathematical ap-
proach in tandem with experimentation, researchers have been able
to model drug release from a variety of stents [27], and ascertain the
dominantmechanisms of release.We refer the reader to a recent review
[27], wheremodelling efforts are summarised in the three categories: 1)
models of drug release from durable and biodegradable polymer coat-
ings; 2)models of drug uptake into arterial tissue, encompassing advec-
tion-diffusion-reaction; and 3) models of coupled drug release and
tissue absorption. Both simple and more sophisticated models covering
analytical andnumerical solutions are described, ranging from1D single
layer convection-diffusion systems to 3D multilayer systems
encompassing anisotropy, nonlinear saturable binding and coupling
with lumenal ﬂow. This review highlights that the model required for
a given application must reﬂect the conditions of the experiment
which the produced the comparison data. The importance of modelling
and experiments being simultaneous approaches is stated and it is
stressed that the accuracy of the outputs of a model are only ever as
good as the accuracy of the inputs, especially when the model is partic-
ularly sensitive to changes in one or more parameters.
Sirianni et al. [38], for instance, modelled the drug release from a
commercially available stent and they noted that Fickian diffusion, dis-
solution and osmotic gradient models were able to ﬁt the data of their
experiments well. A good ﬁt to the data was also achievable by varying
the parameters of the model, despite some parameter values being un-
realistic [38]. This only serves to highlight that care must be taken not
only when devising models for a particular application, but also whenorous layer coatedwith a pure drug layer. Reproduced from [37]. In themodel cw, cp and cb
Da and Dw are the apparent and free diffusion coefﬁcients of drug, K is the equilibrium
he location of the moving boundary, expressed in terms of the classical Stefan condition.
ase from the pores is solved numerically, making use of continuity of concentration and
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have been estimated inversely. If a model has several parameters, it
may ﬁt experimental data well but with the subsequent addition of
other parameters, the conﬁdence in themodel is reduced [38]. An alter-
native is to employ a simpler semi-empirical approach (e.g. Peppas
[39]) which includes a smaller number of (non-physical) parameters.
However, a mechanistic modelling approach has a clear advantage
over a semi-empirical approach since the parameters of the model
may (in principle at least) be measured experimentally and once vali-
dated, a mechanistic model may be used in a predictive capacity.
Stents are similar to OIs in terms of drug release mechanisms and
possible coatings, however, the biological environment is different. For
example, stents experience pulsatile blood ﬂow, whereas an orthopae-
dic device may experience an environment in which the main issue is
mechanical loading. However, the differences in biological environment
between stents and OIs does not preclude the use of mathematical
modelling. Indeed, mathematical modelling has been used in many
other drug delivery applications where the drug is exposed to varying
environments. For example, in transdermal drug delivery [40], the
drug is not exposed to appreciable ﬂow, but is faced with the signiﬁcant
barrier provided by the stratum corneum before it can reach the capil-
lary beds; in ocular drug delivery [41] the drug is exposed to the contin-
uous ﬂow of the lacrimal ﬂuid of the eye; and in drug delivery from
tablets [42], the drug is surrounded by the ﬂuid of the stomach and
gastro-intestinal tract. Yet in each of these cases, mathematical model-
ling has been used to predict drug release and to help optimize device
design. Quite often, however, as a result of the huge expense and time
associated with in vivo experiments, drug delivery device manufac-
turers and experimentalists routinely test the release of drug in an in
vitro environment, under static or gentle agitation conditions, irrespec-
tive of the actual biological environment for the application in question.
While these conditions are unlikely to accurately replicate the in vivo
situation, they nonetheless provide one with an idea of the shape of
the release proﬁle, allowing for comparison between different device
designs. Furthermore, it allows for the repeatability of the release proﬁle
to be tested. In addition, when compared with appropriate mathemati-
cal models of the in vitro experiment, insights can be gained into the
mechanism(s) of release. Therefore, mathematical models which simu-
late drug release under static or gentle agitation conditions can still form
an important part of the overall drug release characterisation and re-
lease mechanism understanding process. However, one should not un-
derestimate the importance of properly accounting for the biological
environmentwhen the intention is to comparewith in vivo data. Bozsak
et al. [43], realising this, coupled their model of drug release from stents
with ﬂowing blood in the lumen and drug binding in tissue. They ac-
knowledge that to be able to truly optimize stent design, then such an
approach is necessary.
The current literature highlights the beneﬁts and obstacles of OIs;
however, they are not insurmountable. Drug release from stents was
scrutinised greatly via experimentation and mathematical modelling,
but it has paid off and so perhaps it is time to use mathematical model-
ling of orthopaedic devices to simulate drug release and provide optimal
implant design strategies.
4. Discussion
As we have seen, there are a plethora of experimental approaches in
the literature focussed on examining the potential of drug release from
OIs; however, to the best of our knowledge, there are no mathematical
models of drug release speciﬁc to OIs. In many cases, questions arise
which may not be answered with repeated experiments alone. More-
over, in several of the studies, the authors alluded to theoretical expla-
nations of observed phenomena which they were not able to
substantiate with the experiments alone.We are advocating that math-
ematical modelling could be extremely useful in many of these cases. A
mathematical model would have to consider the experimental setup indetail and include the various parameters that deﬁne the experiment.
With a suitable model, the outcome of a change in the experimental
setup could be predicted, without the need to rerun costly experiments.
A validated model may also help identify the dominant mechanism of
drug release and aid in establishing the relationships between different
parameters and variables.
It is worth considering a coupledmodel as although it is important to
understand the release of drugs from OIs, it would be wise to have an
understanding of the biological environment, including drug/tissue in-
teractions, as this may affect drug release. With these points in mind,
we suggest that experiments should be conducted in tandem with
mathematical modelling. We stress that as well as helping to character-
ise drug release from potential OIs, future experiments must focus on
deﬁning the desired in vivo release proﬁle for the intended application.
It should be noted that themathematical modelling of growth factor re-
lease is possible, however, careful considerationmust be given since the
size of an individual proteinmolecule can bemuch greater than that of a
drug molecule. This may have implications in terms of delivery from
nanostructures and in the derivation of the underlying transport
equations.
The experiments conducted by Gimeno et al. [11] and Perez et al.
[12] feature prototype implant designs with a view to acting as drug-
eluting pins and screws for ﬁxation applications. In these cases, it is im-
portant to consider the geometry of the device. The designs used in the
experiments were very similar and if an orthopaedic devicewere to uti-
lise the ideas of these experiments, they would not necessarily be
smooth on the outer surface i.e. a ﬁxation screw would have threading
and it would be prudent to consider the affect this may have on the re-
lease proﬁle of the drug. The authors have experimentally identiﬁed pa-
rameters which may, in principle, be incorporated into a model,
subsequently varied and then the resulting effect can be observed with-
out the need for more experiments. Also noteworthy is that these ex-
periments additionally focus on the effectiveness of the drug release in
combating bacterial infection associated with orthopaedic surgery. A
coupled mathematical model of bioﬁlm formation and drug release
could help to understand bioﬁlm development in tandemwith the con-
trolled release of antibiotics. This approach could provide important in-
sights such as revealing the timescale over which the bacteria would be
vulnerable to antibiotic treatment and perhaps the necessary drug con-
centration and delivery strategy to eradicate them.
Another factor to consider from these experiments is drug solubility.
In [10,11], the drugs are used in the form of a dry solid and in [11], two
drugs of signiﬁcantly different solubility are used. Since the drug must
dissolve before diffusing out of the device, this process may have an im-
portant impact on the rate of release and perhaps explains the quite dif-
ferent release proﬁles observed for the two drugs considered [11]. A
mathematical model which includes the dissolution process could not
only potentially explain these differences, but also predict the release
proﬁle for other candidate drugs of different solubility, without having
to conduct numerous experiments. One further question that arises
from the experiments in [11] is that the release proﬁles for both drugs
in the 2 oriﬁce case, have very similar release proﬁles, which is perhaps
counter-intuitive. A mathematical model may be able to establish the
connection between drug release and the number of oriﬁces available
for release. One could say that with more oriﬁces, drug release will nat-
urally occurmore quickly, however, theremay be other factors thatmay
not be easily identiﬁable from experimentation alone.
A common feature of the experiments reviewed in this paper is po-
rosity, namely within [10–12,20]. These experiments in someway have
drug diffusing through a porous structure which could be altered to
achieve the desired release proﬁle. However, the properties of the par-
ticular material/device in question will determine the way in which a
mathematical model accounts for the porosity. For example, Gimeno
et al. [10] consider a porous tube, through which the drug can diffuse,
on the other hand, Aghion et al. [20] have the interconnected pores of
the magnesium foam containing drug, which open up as the material
60 D. King, S. McGinty / Journal of Controlled Release 239 (2016) 49–61degrades and so the relation of porosity to drug release is dependent on
the setup. With a particular system in mind, a mathematical model
could establish the importance of porosity in drug release and could
also allude to how to ﬁne-tune the porosity to suit a speciﬁc application.
Biodegradable coatings also feature heavily in the literature, the ex-
periments which examine this phenomenon in this review are [9,17,22,
23]. Drug release in these setups are especially inﬂuenced by the degra-
dation of the coatings used, be they nanoﬁbres, polymers or gels. As
such, a mathematical modelling approach could make use of moving
boundaries to simulate the degradation of coatings suitable for OIs.
Nanotubes for orthopaedic applications have also been examined and
they are a promising method of drug delivery. Aninwene et al. [18]
experimentedwith them and noted that they can act as drug reservoirs.
Although these may not degrade like the coatings mentioned above, a
mathematical model utilising a moving boundary may prove useful,
since ﬂuid penetration will deplete the drug contained in a nanotube.
Themathematical modelling conducted by Tzur-Balter et al. [33] is a
good example of highlighting the beneﬁts of modelling. A mechanistic
model can account for several system characteristics and potentially
provide insight into the interactions of different drug transport phe-
nomena. In the case of Tzur-Balter et al., the time dependent degrada-
tion of the porous structure of the silicon samples was modelled and
given that the model has considerable validity, it captures the essence
of drug release in this particular setting. It establishes that degradation
is a dominant mechanism of drug release in these experiments. The
model presented by Tzur-Balter et al. has many parameters and al-
though increasing the number of parameters may complicate a model,
it does not diminish its usefulness. In fact, doing so can allow one to de-
duce which aspects of a system have greater control on drug release.
The introduction of more parameters into a model can provide greater
degrees of freedomwhich can be beneﬁcial as tailoring the drug release
proﬁle means it can suit a wider array of applications.
The experiment conducted by Kumeria et al. [14] also illustrates the
beneﬁts of mathematical modelling approaches to drug release. In this
instance, the experimental method of evaluating drug release using
reﬂectometric interference spectroscopy whilst under ﬂuid ﬂow condi-
tionswas validated as the results from the experiments in static and dy-
namic conditions were well represented by the modiﬁed Higuchi
model. Kumeria et al. concluded that diffusionwas the governingmech-
anism of release. Backed up by the mathematical approach and the ex-
perimental ﬁndings, they concluded that evaluation of drug release
under dynamic conditions results in a better understanding of the re-
lease from drug delivery platforms utilising a nanoporous layer. It is of
great importance that the mechanisms of drug release are understood
as it allows for the design optimisation of drug-eluting devices. More
applicable experimental methods that simulate in vivo conditions and
the simultaneous mathematical understanding of drug release will
allow this to be attainable. The in situ drug release measurements of
Kumeria et al. are particularly appealing. Traditionally, drug release typ-
ically wasmeasured by taking samples from the releasemedium at var-
ious time points and analysing using either HPLC (High Performance
Liquid Chromatography) or UV mass spectroscopy. Neither of these
methods are ideal, since the removal of drug from the release medium
alters the concentration gradient and consequently is likely to affect
the ﬂux of drug leaving the device. An alternative is to remove the de-
vice from the release medium, which is then analysed. However, some
of the drug close to the surface of the device could potentially be exclud-
ed, resulting in errors in the calculation of drug mass. Neither approach
can easily provide the spatial distribution of drug in the releasemedium.
A number of new technologies are emergingwhich potentially will pro-
vide more accurate measurements, non-destructively and in situ. Some
examples include imagingmass spectroscopy [44], ﬁbre optics [45] and
photometers [46].
Although a mathematical modelling approach could provide valu-
able insight into drug release across awide array of orthopaedic devices,
one must not forget that it is often the case that increasing complexitymay require a numerical solution. This does not diminish the usefulness
of mathematical approaches; however, it is often the case that simpler
models that give rise to analytical solutions can be of more practical
use. The ability to achieve analytical solutions is greatly advantageous
as release proﬁles can be plotted immediately and from these solutions,
one can deduce the governing parameters of drug release. However, it is
usually the case that the setup being modelled has to be simpliﬁed in
order to obtain an analytical solution. One may have to use an idealised
geometry for example, provided there is justiﬁcation. If the net trans-
port of drug from a device is in one direction, or particular features of
the geometry are much greater in size, relative to others, then it may
be suitable to have a mathematical model based on one spatial dimen-
sion. This may seem like a drastic simpliﬁcation but it is often justiﬁable
mathematically. An important point to make is that many of the exper-
iments are conducted in vitro and a useful mathematical model of drug
release from OIs should account for the underlying biological environ-
ment. Release proﬁles obtained via in vitro experiments are not neces-
sarily the same in the in vivo case, however, experiments in vivo will
help deﬁne what the release proﬁle should be and from this themathe-
matical tools available can be put to good use to help in the designing of
drug-releasing OIs.
5. Conclusions
In this review we have highlighted some of the key issues from the
use of OIs and have provided examples of experimental approaches to
aid in the understanding of drug release from OIs via prototype devices,
coatings and materials. Based on the encouraging results of recent ex-
perimental work, we believe that mathematically analysing drug re-
lease from OIs would very likely be a fruitful endeavour. Such an
approach has the potential of accelerating the design of the enhanced
drug-releasing OIs of the future.
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